(Q37322945)

English

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

scientific article published on January 2008

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

title

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19 August 2017

0 references

Jeffrey Weber

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19001147

retrieved

19 August 2017

publication date

1 January 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

19001147

retrieved

19 August 2017

volume

13 Suppl 4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19001147

retrieved

19 August 2017

page(s)

16-25

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19001147

retrieved

19 August 2017

cites work

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.3000

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8523

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8525

Identifiers

DOI

10.1634/THEONCOLOGIST.13-S4-16

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19001147

retrieved

19 August 2017

PubMed publication ID

19001147

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19001147

retrieved

19 August 2017

(Q37322945)

Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)